Entrada Therapeutics to Release Multiple Ascending Dose Phase 1/2 Cohort 1 Duchenne Study Results May 7
TRDA•Entrada Therapeutics will report topline results from the multiple ascending dose portion of its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 in Duchenne muscular dystrophy patients on May 7, 2026. The double-blind, placebo-controlled Cohort 1 data will be presented via investor webcast and conference call at 8:30 a.m. ET.
1. Upcoming Topline Results Announcement
On May 7, 2026 at 8:30 a.m. ET, Entrada Therapeutics will host a live investor webcast and conference call to present topline safety and pharmacodynamic data from Cohort 1 of the Phase 1/2 ELEVATE-44-201 study evaluating ENTR-601-44 in Duchenne muscular dystrophy patients.
2. ELEVATE-44-201 Study Design
The study is a double-blind, placebo-controlled, multiple ascending dose trial assessing ENTR-601-44’s safety, tolerability and target engagement in patients amenable to exon 44 skipping.
3. ENTR-601-44 Program and Pipeline
ENTR-601-44 is the lead oligonucleotide program within a portfolio targeting neuromuscular and retinal diseases; additional exon skipping programs address exons 45, 50 and 51 in Duchenne muscular dystrophy, and a partnered VX-670 program focuses on myotonic dystrophy type 1.
